Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Head Neck. 2010 May;32(5):599-606. doi: 10.1002/hed.21224.

Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience.

Author information

  • 1Section of Hematology and Medical Oncology, University of Wisconsin, Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. amt@medicine.wisc.edu

Abstract

BACKGROUND:

We retrospectively examined the treatment efficacy and toxicity profile of intensity-modulated radiotherapy (IMRT) plus concurrent weekly cisplatin chemotherapy in patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC).

METHODS:

A total of 57 patients with stage III or IV HNSCC were treated with IMRT and concurrent weekly cisplatin (dosed at 30 mg/m(2)) between November 2001 and May 2007. The median prescription dose to the gross tumor volume was 70 Gy (using 2.0-2.2 Gy daily fractions).

RESULTS:

In-field tumor control at 2 years was 89.1%, locoregional control was 85.5%, and overall survival was 86.9%. The median radiation dose delivered was 70 Gy. The mean dose intensity of cisplatin administered was 25.7 mg/m(2)/week.

CONCLUSION:

Comprehensive head and neck IMRT to 70 Gy delivered with weekly cisplatin chemotherapy (30 mg/m(2)) is feasible and generally well tolerated.

PMID:
19757422
[PubMed - indexed for MEDLINE]
PMCID:
PMC3028434
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1
Figure 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for John Wiley & Sons, Inc. Icon for PubMed Central
    Loading ...
    Write to the Help Desk